231
Participants
Start Date
March 29, 2019
Primary Completion Date
February 17, 2022
Study Completion Date
February 17, 2022
PART 1: Double-blind Placebo-controlled
all eligible subjects will receive either tildrakizumab or placebo
PART 2: Double-blind Active Treatment Extension
subjects initially on placebo will be switched over to receive tildrakizumab while subjects initially on tildrakizumab will continue to receive tildrakizumab as per defined schedule
SPARC Site 23, Kogarah
SPARC Site 27, Kogarah
SPARC Site 24, East Melbourne
SPARC Site 25, Carlton
SPARC Site 26, Woolloongabba
SPARC Site 22, Fremantle
SPARC Site 16, New York
SPARC Site 4, Forest Hills
SPARC Site 19, Margate
SPARC Site 21, Coral Gables
SPARC Site 5, Sweetwater
SPARC Site 01, Beachwood
SPARC Site 11, Houston
SPARC Site 17, Cypress
SPARC Site 6, Webster
SPARC Site 9, Los Angeles
SPARC Site 2, Los Angeles
SPARC Site 14, Santa Monica
SPARC Site 18, Encinitas
SPARC Site 12, Huntington Beach
SPARC Site 7, Fountain Valley
SPARC Site 3, Fremont
SPARC Site 20, Portland
SPARC Site 13, East Windsor
SPARC Site 8, Johnston
Sun Pharmaceutical Industries Limited
INDUSTRY